Antimicrobial Stewardship Opportunities in Critically Ill Patients with Gram-Negative Lower Respiratory Tract Infections: A Multicenter Cross-Sectional Analysis

Springer Science and Business Media LLC - Tập 7 - Trang 135-146 - 2017
Kimberly C. Claeys1, Evan J. Zasowski2, Trang D. Trinh2, Abdalhamid M. Lagnf2, Susan L. Davis2, Michael J. Rybak2
1University of Maryland School of Pharmacy, Baltimore, USA
2Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, USA

Tóm tắt

Lower respiratory tract infections (LRTIs) are a major cause of morbidity and death. Because of changes in how LRTIs are defined coupled with the increasing prevalence of drug resistance, there is a gap in knowledge regarding the current burden of antimicrobial use for Centers for Disease Control and Prevention (CDC)-defined LRTIs. We describe the infection characteristics, antibiotic consumption, and clinical and economic outcomes of patients with Gram-negative (GN) LRTIs treated in intensive care units (ICUs). This was a retrospective, observational, cross-sectional study of adult patients treated in ICUs at two large academic medical centers in metropolitan Detroit, Michigan, from October 2013 to October 2015. To meet the inclusion criteria, patients must have had CDC-defined LRTI caused by a GN pathogen during ICU stay. Microbiological assessment of available Pseudomonas aeruginosa isolates included minimum inhibitory concentrations for key antimicrobial agents. Four hundred and seventy-two patients, primarily from the community (346, 73.3%), were treated in medical ICUs (272, 57.6%). Clinically defined pneumonia was common (264, 55.9%). Six hundred and nineteen GN organisms were identified from index respiratory cultures: P. aeruginosa was common (224, 36.2%), with 21.6% of these isolates being multidrug resistant. Cefepime (213, 45.1%) and piperacillin/tazobactam (174, 36.8%) were the most frequent empiric GN therapies. Empiric GN therapy was inappropriate in 44.6% of cases. Lack of in vitro susceptibility (80.1%) was the most common reason for inappropriateness. Patients with inappropriate empiric GN therapy had longer overall stay, which translated to a median total cost of care of $79,800 (interquartile range $48,775 to $129,600) versus $68,000 (interquartile range $38,400 to $116,175), p = 0.013. Clinical failure (31.5% vs 30.0%, p = 0.912) and in-hospital all-cause mortality (26.4% vs 25.9%, p = 0.814) were not different. Drug-resistant pathogens were frequently found and empiric GN therapy was inappropriate in nearly 50% of cases. Inappropriate therapy led to increased lengths of stay and was associated with higher costs of care.

Tài liệu tham khảo

Hugonnet S, Eggimann P, Borst F, et al. Impact of ventilator-associated pneumonia on resource utilization and patient outcome infection control and hospital epidemiology. Infect Control Hosp Epidemiol. 2004;25(12):1090–6.

Centers for Disease Control and Prevention (CDC). November 2015 Update-CRE Toolkit; 2012. https://www.cdc.gov/hai/pdfs/cre/CRE-guidance-508.pdf. Accessed Feb 2017.

Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115(2):462–74.

Centers for Disease Control and Prevention. CDC/NHSN surveillance definitions for specific types of infections. 2013. http://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf Accessed 9 Oct 2016.

Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-third informational supplement. CLSI document M100–S23. Wayne, (PA): Clinical and Laboratory Standards Institute; 2013.

American Hospital Association. AHA Annual Survey Database. 2015. https://www.ahadataviewer.com/book-cd-products/AHA-Survey/. Accessed 15 Dec 2016.

American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388–416.

Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry—hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia: developing drugs for treatment. 2014. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm234907.pdf. Accessed 12 Feb 2017.

Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–111.